CELLDEX THERAPEUTICS INC
CLDXNASDAQ🏆 #1784 by market capEarnings Nov 11US Equity
$29.66▼ $0.49 (−1.63%)
🌅 Pre-market$29.40▼ 0.88%Regular close · extended-hours price shownTrack CLDX
Get earnings, price moves & breaking news on Telegram
24h▼ 1.6%
7d▲ 2.4%
14d▲ 2.6%
30d▼ 6.2%
ytd▲ 9.2%
1y▲ 14.3%
🏦Market Cap
$2.33B
Small Cap
📈Revenue Growth (YoY)
-97.3%
Declining
📊Gross Margin
17.6%
Thin
💵FCF Margin
19708.9%
Strong
⚖️P/S Ratio
15010.1x
Expensive
Otter Score
32
Weak
CELLDEX THERAPEUTICS INC
CLDXAnalyst Ratings
Price
$29.66
Total
20
Raised
0
Lowered
2
Avg PT
$66.80
H / L
$100 / $45
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-10-02 | — | — |
Leerink Partners | Reiterated | Outperform | 2026-09-23 | $88.00 | +196.70% |
Morgan Stanley | Reiterated | Overweight | 2026-09-23 | $57.00 | +92.20% |
Cantor Fitzgerald | Reiterated | Overweight | 2026-09-22 | $61.00 | +105.70% |
Barclays | Reiterated | Overweight | 2026-08-07 | $53.00 | +78.70% |
Wells Fargo | Reiterated | Overweight | 2026-07-29 | $72.00 | +142.80% |
Canaccord Genuity | Reiterated | Buy | 2026-07-22 | $60.00 | +102.30% |
Guggenheim | Reiterated | Buy | 2026-07-20 | $100.00 | +237.20% |
UBS | Reiterated | Buy | 2026-06-10 | $45.00 | +51.70% |
Goldman Sachs | Reiterated | Neutral | 2026-03-02 | — | — |
Stifel | Reiterated | Buy | 2026-02-26 | — | — |
Citigroup | Reiterated | Buy | 2025-08-20 | — | — |
SVB Leerink | Reiterated | Outperform | 2022-08-09 | — | — |
Jefferies | Reiterated | Buy | 2021-09-17 | — | — |
Wedbush | Downgraded | Outperform → Neutral | 2020-11-25 | — | — |
Oppenheimer | Downgraded | Outperform → Perform | 2020-11-25 | — | — |
Leerink Swann | Reiterated | Market Perform → Perform | 2020-11-25 | — | — |
Cowen & Co. | Reiterated | Outperform | 2020-11-25 | — | — |
H.C. Wainwright | Reiterated | Buy | 2020-11-25 | $64.00 | +115.80% |
Aegis Capital | Reiterated | Buy | 2016-11-07 | — | — |
Institution
HC Wainwright & Co.
Reiterated · Buy · 2026-10-02
—
—
Leerink Partners
Reiterated · Outperform · 2026-09-23
$88.00
+196.70%
Morgan Stanley
Reiterated · Overweight · 2026-09-23
$57.00
+92.20%
Cantor Fitzgerald
Reiterated · Overweight · 2026-09-22
$61.00
+105.70%
Barclays
Reiterated · Overweight · 2026-08-07
$53.00
+78.70%
Wells Fargo
Reiterated · Overweight · 2026-07-29
$72.00
+142.80%
Canaccord Genuity
Reiterated · Buy · 2026-07-22
$60.00
+102.30%
Guggenheim
Reiterated · Buy · 2026-07-20
$100.00
+237.20%
UBS
Reiterated · Buy · 2026-06-10
$45.00
+51.70%
Goldman Sachs
Reiterated · Neutral · 2026-03-02
—
—
Stifel
Reiterated · Buy · 2026-02-26
—
—
Citigroup
Reiterated · Buy · 2025-08-20
—
—
SVB Leerink
Reiterated · Outperform · 2022-08-09
—
—
Jefferies
Reiterated · Buy · 2021-09-17
—
—
Wedbush
Downgraded · Outperform → Neutral · 2020-11-25
—
—
Oppenheimer
Downgraded · Outperform → Perform · 2020-11-25
—
—
Leerink Swann
Reiterated · Market Perform → Perform · 2020-11-25
—
—
Cowen & Co.
Reiterated · Outperform · 2020-11-25
—
—
H.C. Wainwright
Reiterated · Buy · 2020-11-25
$64.00
+115.80%
Aegis Capital
Reiterated · Buy · 2016-11-07
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space